Surmodics (NASDAQ:SRDX) Has Target Of $55 Give by Analysts at Needham. Buy Didn’t change.

May 17, 2018 - By Jason Dias

Surmodics, Inc. (NASDAQ:SRDX) Corporate Logo

During 2017 Q4 the big money sentiment decreased to 0.69. That’s change of 0.25, from 2017Q3’s 0.94. 11 investors sold all, 44 reduced holdings as Surmodics, Inc. ratio worsened. 26 rose positions while 12 funds amassed positions. Funds hold 11.07 million shares thus 0.98% less from 2017Q3’s 11.18 million shares.

Bancshares Of Montreal Can holds 0% or 2,170 shs in its capital. Blackrock Inc invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Moreover, Gamco Invsts Et Al has 0.02% invested in Surmodics, Inc. (NASDAQ:SRDX). Schwab Charles Invest Management Inc has 62,235 shs for 0% of their capital. Dimensional Fund Advsr Lp reported 636,801 shs stake. Legal & General Group Public owns 23,854 shs or 0% of their US capital. D E Shaw Communication invested in 88,541 shs or 0% of the stock. Parkside Bancshares Trust reported 15 shs or 0% of all its holdings. Spark Management Limited Com stated it has 8,400 shs or 0.01% of all its holdings. 33,653 were reported by Guggenheim Cap Limited Liability Com. Invesco Ltd holds 0% or 44,719 shs in its capital. 10,490 were reported by Manufacturers Life Ins The. Tci Wealth Advsrs reported 33 shs. American Inc reported 0% in Surmodics, Inc. (NASDAQ:SRDX). Tower Rech Capital Ltd (Trc) accumulated 0% or 530 shs.

Surmodics, Inc. had 2 selling transactions and 0 buys since December 11, 2017. This’s net activity of $63,711.

Reiterated Surmodics (NASDAQ:SRDX) Rating.

New York: On Wednesday morning, an analyst note was issued to clients of Surmodics (NASDAQ:SRDX). Its Buy Rating reiterated by Analysts at Needham. Stock analysts have target price per share of $55 which gives 11.79 % upside potential on firm’s stock.

Surmodics, Inc. (NASDAQ:SRDX) Ratings Coverage

In total 2 analysts cover Surmodics (NASDAQ:SRDX). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. With $5500 highest and $42 lowest target price Surmodics has $55 average target price or 11.79% above the current ($49.2) price. 4 are the (NASDAQ:SRDX)’s analyst reports since February 28, 2018 according to StockzIntelligence Inc. In Wednesday, February 28 report Barrington Research upgraded the stock to “Outperform” rating. The stock rating was maintained by Needham with “Buy” on Wednesday, May 2. On Wednesday, May 16 the stock of Surmodics, Inc. (NASDAQ:SRDX) earned “Buy” rating by Needham.

SRDX is touching $49.2 during the last trading session, after increased 5.24%.Surmodics, Inc. has 114,997 shares volume, 113.73% up from normal. SRDX is uptrending and has moved 61.37% since May 17, 2017. SRDX outperformed the S&P 500 by 49.82%.

Surmodics, Inc. (NASDAQ:SRDX)’s quarterly earnings will be announced on August, 2., according to Zacks. EPS of $-0.08 is 188.89 % down from 2017’s $0.09 EPS. Wall Street sees -214.29 % negative EPS growth as of August, 2.

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland.The firm is valued at $652.29 million. It operates through two divisions, Medical Device and In Vitro Diagnostics.The P/E ratio is 24600. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

For more Surmodics, Inc. (NASDAQ:SRDX) news published recently go to:,,, or The titles are as follows: “Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole …” published on May 14, 2018, “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” on May 09, 2018, “SurModics CFO LaFrence leaves for pharma company” with a publish date: May 16, 2018, “Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA …” and the last “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” with publication date: May 15, 2018.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: